GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Spectral Medical Inc (TSX:EDT) » Definitions » Return-on-Tangible-Equity

Spectral Medical (TSX:EDT) Return-on-Tangible-Equity : 0.00% (As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Spectral Medical Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Spectral Medical's annualized net income for the quarter that ended in Mar. 2024 was C$-16.64 Mil. Spectral Medical's average shareholder tangible equity for the quarter that ended in Mar. 2024 was C$-18.53 Mil. Therefore, Spectral Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was N/A%.

The historical rank and industry rank for Spectral Medical's Return-on-Tangible-Equity or its related term are showing as below:

TSX:EDT's Return-on-Tangible-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -1.4
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Spectral Medical Return-on-Tangible-Equity Historical Data

The historical data trend for Spectral Medical's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectral Medical Return-on-Tangible-Equity Chart

Spectral Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -120.25 -1,681.70 -597.62 -2,069.91 -

Spectral Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Spectral Medical's Return-on-Tangible-Equity

For the Diagnostics & Research subindustry, Spectral Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spectral Medical's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Spectral Medical's Return-on-Tangible-Equity falls into.



Spectral Medical Return-on-Tangible-Equity Calculation

Spectral Medical's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-15.662/( (-2.765+-16.742 )/ 2 )
=-15.662/-9.7535
=N/A %

Spectral Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-16.64/( (-16.742+-20.326)/ 2 )
=-16.64/-18.534
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Spectral Medical  (TSX:EDT) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Spectral Medical Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Spectral Medical's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Spectral Medical (TSX:EDT) Business Description

Traded in Other Exchanges
Address
135 - 2 The West Mall, Finance, Toronto, ON, CAN, M9C 1C2
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. The company has one reporting segment Spectral Medical Inc. The Dialco Medical Inc. operations were considered discontinued by the company.
Executives
Anthony Phillip Bihl Director
William Charles Stevens Director

Spectral Medical (TSX:EDT) Headlines